Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Gopal

Showing results (311-320 of 372) with videos related to

Pageof 38
Sort By:
Blood|October 26, 2000
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomasO W Press, J F Eary, T Gooley, et al.
The Lancet. Haematology|July 30, 2021
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 studyRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2013
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantationRyan D Cassaday, Katherine A Guthrie, Elizabeth L Budde, et al.
Hydrogeology Journal|February 7, 2020
Hydrogeological typologies of the Indo-Gangetic basin alluvial aquifer, South AsiaH C Bonsor, A M MacDonald, K M Ahmed, et al.
British Journal of Haematology|October 13, 2015
High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphomaRyan D Cassaday, Philip A Stevenson, Theodore A Gooley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2015
Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphomaS A Graf, P A Stevenson, L A Holmberg, et al.
Bone Marrow Transplantation|July 26, 2020
<sup>90</sup>Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myelomaSherilyn A Tuazon, Brenda M Sandmaier, Theodore A Gooley, et al.
Blood|April 19, 2022
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHLJordan Gauthier, Nicolas Gazeau, Alexandre V Hirayama, et al.
Transplantation and Cellular Therapy|September 27, 2020
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory LymphomaSherilyn A Tuazon, Ryan D Cassaday, Theodore A Gooley, et al.
Haematologica|March 13, 2025
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow upAndrew J Portuguese, Jennifer J Huang, Yein Jeon, et al.
Pageof 38

Showing results (311-320 of 372) with videos related to

Sort By:
Pageof 38
Blood|October 26, 2000
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomasO W Press, J F Eary, T Gooley, et al.
The Lancet. Haematology|July 30, 2021
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 studyRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2013
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantationRyan D Cassaday, Katherine A Guthrie, Elizabeth L Budde, et al.
Hydrogeology Journal|February 7, 2020
Hydrogeological typologies of the Indo-Gangetic basin alluvial aquifer, South AsiaH C Bonsor, A M MacDonald, K M Ahmed, et al.
British Journal of Haematology|October 13, 2015
High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphomaRyan D Cassaday, Philip A Stevenson, Theodore A Gooley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2015
Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphomaS A Graf, P A Stevenson, L A Holmberg, et al.
Bone Marrow Transplantation|July 26, 2020
<sup>90</sup>Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myelomaSherilyn A Tuazon, Brenda M Sandmaier, Theodore A Gooley, et al.
Blood|April 19, 2022
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHLJordan Gauthier, Nicolas Gazeau, Alexandre V Hirayama, et al.
Transplantation and Cellular Therapy|September 27, 2020
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory LymphomaSherilyn A Tuazon, Ryan D Cassaday, Theodore A Gooley, et al.
Haematologica|March 13, 2025
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow upAndrew J Portuguese, Jennifer J Huang, Yein Jeon, et al.
Pageof 38